Inhibikase Therapeutics, Inc.

Healthcare

NASDAQ:IKT · NASDAQ Capital Market

Market Cap $221.15M Beta 0.97 P/E (TTM) -3.2

$1.67 +0.00%

+$0.00 today

52W Low $1.33High $2.26

Vol 0.42M · Avg 1.06M

EPS (TTM)-$0.52

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-10.22%

Period High

$2.14

Period Low

$1.41

Latest

$1.67

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Greenwich LifeSciences, Inc.

NASDAQ:GLSI

$353.16M

Turn Therapeutics Inc.

NASDAQ:TTRX

$180.07M

Surrozen, Inc.

NASDAQ:SRZN

$174.90M

Agenus Inc.

NASDAQ:AGEN

$137.42M

Cognition Therapeutics, Inc.

NASDAQ:CGTX

$89.03M

Entera Bio Ltd.

NASDAQ:ENTX

$60.63M

eXoZymes, Inc.

NASDAQ:EXOZ

$60.20M

Estrella Immunopharma, Inc.

ESLA

$45.62M

Tevogen Bio Holdings Inc.

TVGN

$43.84M

Atossa Therapeutics, Inc.

ATOS

$21.18M

What is the latest IKT filing?

The latest filing shown is SC 13G/A dated May 15, 2026.

How many recent filings does IKT have?

Intrinsic Alpha currently shows 20 recent filings for IKT.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.